Related Experiment Video
Updated: Jul 11, 2026
07:01
Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
Chemically modified siRNA prolonged RNA interference in renal disease
Yoshitsugu Takabatake1, Yoshitaka Isaka, Masayuki Mizui
1Department of Nephrology, Osaka University Graduate School of Medicine (A8), Suita 565-0871, Japan.
Biochemical and Biophysical Research Communications
|September 21, 2007
Summary
Chemically modified siRNAs (siSTABLE) targeting TGF-beta1 show prolonged silencing of gene expression in kidney disease models. This RNA interference therapy offers a promising strategy for progressive renal diseases.
Area of Science:
- Molecular Biology
- Genetics
- Nephrology
Background:
- Short interfering RNAs (siRNAs) effectively silence TGF-beta1 in glomerulonephritis models.
- A key challenge for RNA interference (RNAi) gene therapy is maintaining prolonged in vivo silencing.
- TGF-beta1 plays a crucial role in the progression of kidney diseases.
Purpose of the Study:
- To investigate the duration of siRNA stability in kidney and muscle tissues.
- To determine the tissue distribution of the siRNase eri-1.
- To evaluate the therapeutic potential of chemically modified, eri-1-resistant siRNAs in a progressive glomerulosclerosis model.
Main Methods:
- Examined siRNA stability and eri-1 expression in kidney and muscle.
- Utilized a chemically modified siRNA (siSTABLE) designed for enhanced stability.
- Tested siSTABLE targeting TGF-beta1 in a progressive glomerulosclerosis mouse model.
Main Results:
- siRNA targeting EGFP showed transient silencing (2 weeks) in kidneys but prolonged silencing (>90 days) in muscle, correlating with eri-1 expression levels.
- ERI-1 resistant siSTABLE targeting TGF-beta1 significantly reduced glomerular matrix deposition.
- Demonstrated differential siRNA stability in various tissues influenced by siRNase activity.
Conclusions:
- siRNA stability varies significantly between kidney and muscle tissues due to differential eri-1 expression.
- ERI-1 resistant siRNAs represent a promising therapeutic strategy for managing progressive renal diseases.
- RNA interference targeting TGF-beta1 with stabilized siRNAs holds potential for treating kidney fibrosis.
Related Concept Videos
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...